Health Canada Approves KEYTRUDA^® (pembrolizumab) for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

Health Canada Approves GARDASIL^®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the Prevention of Oropharyngeal and Other Head and Neck Cancers

Learn more

Update on our support for Ukraine

Learn more

Merck Canada Announces Expansion of Manufacturing for Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19

Learn more

Merck Canada Announces Supply Agreement of Up to 1 Million Patient Courses of Molnupiravir, an Investigational Oral Antiviral Medicine for the Treatment of COVID-19, with the Government of Canada

Learn more

COVID-19: How We Are Responding

Learn more

Kingston Health Sciences Centre Expands Lung Diagnostic Assessment Program to Napanee, ON

Learn more

It’s time to get back on track with routine care

Learn more

Don’t delay if you think you’re at risk of lung cancer

Learn more

Health Canada Approves KEYTRUDA^® (pembrolizumab) in Combination with Chemotherapy for the Treatment of Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

Learn more

Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study

Learn more

Media library

Marwan Akar Appointed as President & Managing Director of Merck Canada

Learn more

Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection

Learn more

Watch Merck Chief Patient Officer Dr. Julie Gerberding and other panelists discuss what the new normal will look like for Canadians and companies as we move towards a post pandemic economy.

Learn more

Merck Canada Announces Start of Enrollment for Phase 3 Clinical Trial of Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19

Learn more

Merck Canada and MaRS Announce Winners of the Lung Cancer Innovation Challenge

Learn more

Vaccine Confidence

Learn more

Health Canada Approves KEYTRUDA^® (pembrolizumab) as First-line Treatment for Adults with Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

Learn more

Are you a healthcare professional with questions or comments about our products?

Submit a
Medical
Inquiry

Report an
Adverse
Event

Report a
Product
Complaint

Submit
General
Feedback

Submit a
Product Stability
Request

Submit a Medical Inquiry

Report an Adverse Event

Report a Product Complaint

Submit General Feedback

Submit a Product Stability Request

AskMerck.ca can help you find what you need.

Visit AskMerck.ca

Merck's Commitment to Antimicrobial Innovation

Learn more

We have always been and always will be inventing, and we do it for the single greatest purpose: life.

Learn more

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.